ArticleInternational journal of oncology2011
Role of endogenous cholecystokinin on growth of human pancreatic cancer.
Article in International journal of oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review.Signal transduction and targeted therapy · 2023Pooled it
- Cholecystectomy and the risk of alimentary tract cancers: a systematic review.World journal of gastroenterology · 2015Pooled it
- Target-Specific Locked Nucleic Acid Gapmer Decreases Growth and Metastases of Pancreatic Cancer.Molecular cancer therapeutics · 2025Article
- Target-Specific Nanoparticle Polyplex Down-Regulates MutantInternational journal of molecular sciences · 2023Article
- TGFβ Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFβ Induced EMT in PDAC.Cancers · 2021Article
- Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas.Biomolecules · 2021Article
- Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model.Cancer prevention research (Philadelphia, Pa.) · 2021Article
- Gastrin, Cholecystokinin, Signaling, and Biological Activities in Cellular Processes.Frontiers in endocrinology · 2020Review
- Article
- Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer.Cellular and molecular gastroenterology and hepatology · 2018Article
- The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies.International journal of biological sciences · 2016Review
- Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival.Pancreas · 2015Article
- Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.Pancreas · 2014Article
- Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.World journal of gastroenterology · 2014Review
- Cholecystokinin and pancreatic cancer: the chicken or the egg?American journal of physiology. Gastrointestinal and liver physiology · 2014Review
- Evolution of a potential hormone antagonist following gene splicing during primate evolution.PloS one · 2013Article
- NIR-activated content release from plasmon resonant liposomes for probing single-cell responses.ACS nano · 2012Article
- Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis.American journal of physiology. Gastrointestinal and liver physiology · 2012Article
- Systems analysis of a mouse xenograft model reveals annexin A1 as a regulator of gene expression in tumor stroma.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Cholecystokinin (CCK) and gastrin stimulate growth of pancreatic cancer. Although down-regulation of gastrin inhibits growth of pancreatic cancer, the contribution of endogenous CCK to tumor growth is unknown. The purpose of this study was to evaluate the role of endogenous CCK on autocrine growth of pancreatic cancer. Pancreatic cancer cell lines were analyzed for CCK mRNA and peptide expression by real-time RT-PCR and radioimmunoassay, respectively. The effect of endogenous CCK on growth was evaluated by treating cancer cells with CCK neutralizing antibodies and by down-regulating CCK mRNA by RNAi. Wild-type pancreatic cancer cells expressed significantly lower CCK mRNA and peptide levels than gastrin. Neither treatment of pancreatic cancer cells with CCK antibodies nor the down-regulation of CCK mRNA and peptide by shRNAs altered growth in vitro or in vivo. Conversely, when gastrin mRNA expression was down-regulated, the same cells failed to produce tumors in spite of having sustained levels of endogenous CCK. Pancreatic cancer cells produce CCK and gastrin; however, the autocrine production of gastrin is more important for stimulating tumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.